A carbohydrate-based drug candidate, STC3141, has successfully concluded its Phase 2 clinical trial in China for the treatment of sepsis. The trial met its key endpoints, leading to plans by Grand Pharmaceutical Group Limited (Grand Pharma) to advance the drug to a Phase 3 trial.
Clinical Trial Outcomes
The Phase 2 clinical trial for STC3141 involved 180 sepsis patients and was conducted in China by Grand Pharmaceutical Group Limited. The trial results indicated that the drug candidate met key endpoints, suggesting effectiveness in reducing sepsis in human patients. Following these outcomes, Grand Pharma plans to proceed with a Phase 3 trial to further assess the treatment's efficacy.
Drug Development and Mechanism
STC3141 is a carbohydrate-based small-molecule drug. Its development involved research teams led by Professor Mark von Itzstein AO at Griffith University's Institute for Biomedicine and Glycomics, alongside Professor Christopher Parish and his team at The Australian National University.
Administered via infusion, STC3141 is designed to counteract a specific biological molecule release phenomenon that occurs during sepsis. The drug is intended to treat the condition by reversing organ damage.
Understanding Sepsis
Sepsis is a medical condition that affects millions of hospitalized patients globally each year. It occurs when the body's immune response to an infection becomes dysregulated and begins to attack its own tissues and organs. If not identified and managed promptly, sepsis can lead to septic shock, multiple organ failure, and death. Currently, there is no specific anti-sepsis therapy available.
Future Prospects
Professor Mark von Itzstein has stated that the treatment could potentially reach the market within a few years. He has also indicated that the drug is believed to hold the potential to save millions of lives.